Progress of phosphatidylinositol 3-kinase signaling pathway and its inhibitors in lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 568-571, 2019.
Artículo
en Chino
| WPRIM
| ID: wpr-751443
ABSTRACT
The over-activation of phosphatidylinositol 3-kinase (PI3K) signaling pathway is closely related to the occurrence and development of malignant tumors. The abnormal expression of this pathway is involved in the regulation of cell growth, malignant transformation, apoptosis and metastasis. The targeted therapy for specific sites of PI3K signaling pathway is a new research hotspot. A variety of different types of PI3K inhibitors have been marketed or entered clinical trials and have shown considerable efficacy in the treatment of malignant lymphomas. In this view, the recent advances in activation patterns of PI3K signaling pathway in lymphoma and PI3K inhibitors are summarized.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of Leukemia & Lymphoma
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS